Literature DB >> 15707585

The tumor suppressor PTEN inhibits EGF-induced TSP-1 and TIMP-1 expression in FTC-133 thyroid carcinoma cells.

Mahdhia Soula-Rothhut1, Cyrille Coissard, Hervé Sartelet, Cédric Boudot, Georges Bellon, Laurent Martiny, Bernard Rothhut.   

Abstract

Thrombospondin-1 (TSP-1) is a multidomain extracellular macromolecule that was first identified as natural modulator of angiogenesis and tumor growth. In the present study, we found that epidermal growth factor (EGF) up-regulated TSP-1 expression in FTC-133 (primary tumor) but not in FTC-238 (lung metastasis) thyroid cancer cells. Both EGF and TSP-1 induced expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in a mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and phosphatidylinositol 3-kinase (PI3-kinase)-dependent manner. In FTC-133 cells, EGF induced proliferation in a TSP-1- and TIMP-1-dependent manner. In addition, we determined that re-expression of the tumor suppressor protein PTEN induced cell death, an effect that correlated with a block of Akt kinase phosphorylation. EGF-induced TSP-1 and TIMP-1 promoter activity and protein expression were inhibited in FTC-133 cells stably expressing wtPTEN but not in cells expressing mutant PTEN. Furthermore, we found that wtPTEN inhibited EGF--but not TSP-1--stimulated FTC-133 cell migration and also inhibited invasion induced by EGF and by TSP-1. Finally, an antibody against TSP-1 reversed EGF-stimulated FTC-133 cell invasion as well as the constitutive invasive potential of FTC-238 cells. Overall, our results suggest that PTEN can function as an important modulator of extracellular matrix proteins in thyroid cancer. Therefore, analyzing differential regulation of TSP-1 by growth factors such as EGF can be helpful in understanding thyroid cancer development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15707585     DOI: 10.1016/j.yexcr.2004.10.026

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  12 in total

1.  Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1.

Authors:  Markus Wagner; Vincent Roh; Michael Strehlen; Alexander Laemmle; Deborah Stroka; Bernhard Egger; Markus Trochsler; Kelly K Hunt; Daniel Candinas; Stephan A Vorburger
Journal:  J Gastrointest Surg       Date:  2009-06-30       Impact factor: 3.452

2.  Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.

Authors:  Michael W Yeh; Jean-Philippe Rougier; Jin-Woo Park; Quan-Yang Duh; Mariwil Wong; Zena Werb; Orlo H Clark
Journal:  Endocr Relat Cancer       Date:  2006-12       Impact factor: 5.678

3.  Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo.

Authors:  Juhua Chen; Payaningal R Somanath; Olga Razorenova; William S Chen; Nissim Hay; Paul Bornstein; Tatiana V Byzova
Journal:  Nat Med       Date:  2005-10-16       Impact factor: 53.440

4.  Identification of soluble tissue-derived biomarkers from human thyroid tissue explants maintained on a microfluidic device.

Authors:  Andrew Riley; Heidi Jones; James England; Dmitriy Kuvshinov; Victoria Green; John Greenman
Journal:  Oncol Lett       Date:  2021-09-13       Impact factor: 2.967

5.  Epidermal growth factor-like repeats of thrombospondins activate phospholipase Cgamma and increase epithelial cell migration through indirect epidermal growth factor receptor activation.

Authors:  Anguo Liu; Pallavi Garg; Shiqi Yang; Ping Gong; Manuel A Pallero; Douglas S Annis; Yuanyuan Liu; Antonino Passaniti; Dean Mann; Deane F Mosher; Joanne E Murphy-Ullrich; Simeon E Goldblum
Journal:  J Biol Chem       Date:  2009-01-07       Impact factor: 5.157

6.  Extracellular matrix proteins modulate antimigratory and apoptotic effects of Doxorubicin.

Authors:  Georges Said; Marie Guilbert; Hamid Morjani; Roselyne Garnotel; Pierre Jeannesson; Hassan El Btaouri
Journal:  Chemother Res Pract       Date:  2012-07-01

Review 7.  Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.

Authors:  Marco Rusnati; Chiara Urbinati; Silvia Bonifacio; Marco Presta; Giulia Taraboletti
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-23

8.  Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein.

Authors:  Laura A Laviolette; Julien Mermoud; Isabel A Calvo; Nicholas Olson; Myriam Boukhali; Ortrud K Steinlein; Elisabeth Roider; Elke C Sattler; Dachuan Huang; Bin Tean Teh; Mo Motamedi; Wilhelm Haas; Othon Iliopoulos
Journal:  Nat Commun       Date:  2017-06-28       Impact factor: 14.919

9.  Effects of radioiodine administration on serum concentrations of matrix metalloproteinases, adiponectin and thrombospondin-1.

Authors:  Andrzej Lewinski; Anna Brona; Krzysztof C Lewandowski; Diana Jedrzejuk; Anna Bohdanowicz-Pawlak; Elżbieta Skowronska-Jozwiak; Małgorzata Bienkiewicz; Andrzej Milewicz
Journal:  Thyroid Res       Date:  2013-08-06

10.  TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.

Authors:  Line S Tarpgaard; Maj Sofie Ørum-Madsen; Ib J Christensen; Cathrine Nordgaard; Julie Noer; Tormod K Guren; Bengt Glimelius; Halfdan Sorbye; Tone Ikdahl; Elin H Kure; Kjell M Tveit; Hans J Nielsen; Per Pfeiffer; Nils Brünner; José M A Moreira
Journal:  Oncotarget       Date:  2016-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.